莫西沙星治疗老年呼吸道感染的有效性与安全性评价

发布时间：2018-03-25 07:53

本文选题：莫西沙星　切入点：呼吸道感染　出处：《中华医院感染学杂志》2015年10期

【摘要】：目的分析莫西沙星治疗老年呼吸道感染的有效性与安全性,为提高该类患者的临床疗效提供参考依据。方法选取医院2012年1月-2013年12月收治的236例老年呼吸道感染患者,将其随机平分为莫西沙星治疗组(A组)和左氧氟沙星治疗组(B组),各118例,分别使用莫西沙星与左氧氟沙星治疗,对比分析两组患者的临床疗效、不良反应发生率以及治疗前后病原学检查结果;采用SPSS19.0软件对数据进行统计分析。结果 A组患者治疗有效率为94.9%,明显高于B组的80.5%,两组比较差异有统计学意义(P0.05);A组细菌清除率为91.2%,明显高于B组的69.7%,两组比较差异有统计学意义(P0.05);A、B两组患者不良反应发生率分别为6.78%和5.93%,差异无统计学意义,且症状均较轻微,经进一步治疗后即可痊愈。结论莫西沙星治疗老年呼吸道感染患者不良反应发生率低,临床见效快,且疗效显著,可缩短患者住院时间、节省就医成本。
[Abstract]:Objective to analyze the efficacy and safety of moxifloxacin in the treatment of elderly patients with respiratory tract infection, and to provide a reference for improving the clinical efficacy of these patients. Methods 236 elderly patients with respiratory tract infection were selected from January 2012 to December 2013. They were randomly divided into two groups: moxifloxacin group (n = 118) and levofloxacin group (n = 118). The incidence of adverse reactions and the results of etiological examination before and after treatment; Results the effective rate of treatment in group A was 94.9, which was significantly higher than that in group B (80.5). The bacterial clearance rate in group A was 91.2, which was significantly higher than that in group B (P 0.05), which was significantly higher than that in group B (69.7%). The incidence of adverse reactions in the two groups was 6.78% and 5.93%, respectively. There was no significant difference between the two groups. Conclusion moxifloxacin in the treatment of elderly patients with respiratory tract infection has a low incidence of adverse reactions, rapid clinical efficacy, and significant curative effect, can shorten the hospitalization time of patients and save the cost of medical treatment.
【作者单位】：贵州省人民医院干部医疗科;
【基金】：贵州省科学技术基金资助项目(黔科合LS字2012-032)
【分类号】：R56

【参考文献】